Be my Valentine: Attractive gut assets win Elcelyx loving $20m
This article was originally published in Scrip
Executive Summary
Venture capital investors expressed their love for San Diego-based Elcelyx Therapeutics' type 2 diabetes drug candidate NewMet and over-the-counter weight loss supplement Lovidia on Valentine's Day by closing a $20 million Series C venture funding round to prepare the assets for partnerships and commercialization.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.